Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltri...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Iweha, Chioma, Salgado, Luiz, Mazzuco, Tania Longo, Campigotto, Federico, Maamari, Ricardo, Limumpornpetch, Padiporn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646464/
https://www.ncbi.nlm.nih.gov/pubmed/31379734
http://dx.doi.org/10.3389/fendo.2019.00436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646464/
https://www.ncbi.nlm.nih.gov/pubmed/31379734
http://dx.doi.org/10.3389/fendo.2019.00436

Ejemplares similares